News | News By Subject | News by Disease News By Date | Search News

Hemophilia A News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Pfizer (PFE) Makes a $545 Million Deal With Another Bay Area Biotech, Sangamo (SGMO)     5/12/2017
Why All Eyes Will be on Alnylam (ALNY) and Any Updates of Its APOLLO Phase III Trial This Friday     5/11/2017
Genentech (RHHBY) Shows Off Late-Stage Hemophilia A Data     4/17/2017
One Death in the HAVEN 1 Trial Complicates Roche (RHHBY)’s Entry into the Hemophilia A Market     3/13/2017
Roche (RHHBY) Reports Death in Phase III Hemophilia Study     2/27/2017
Roche (RHHBY) Takes a Win as Emicizumab Hemophilia Drug Succeeds in Phase III     12/22/2016
Sources Reveal Biogen (BIIB) is Exploring Sale of Hemophilia Assets     4/12/2016
FDA Gives Thumbs Up to Bayer (BAY)'s Hemophilia A Drug Kovaltry     3/17/2016
FDA Green Lights Octapharma USA's NUWIQ for Hemophilia A     9/15/2015
Genentech (RHHBY)’s Hemophilia A Drug Gets Breakthrough Designation in Potential $11 Billion Market     9/10/2015
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review     3/17/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Baxter International, Inc. (BAX)'s Hemophilia A Drug Obizur Wins FDA Approval     10/24/2014

News from Around the Web

Press Releases
MacroGenics (MGNX) Presents Updated Data From Phase I Study Of MGD010 At Annual European Congress Of Rheumatology (EULAR 2017)     6/19/2017
Bioverativ (BIVV) Announces FDA Acceptance Of Investigational New Drug Application For BIVV001 To Treat Hemophilia A     6/12/2017
Sangamo (SGMO) And Pfizer (PFE) Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The EMA     6/7/2017
Shire (SHPG)'s Hemophilia A Drug Flunks Tiny Phase I Trial     5/22/2017
Sangamo (SGMO) Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy     5/16/2017
uniQure (QURE) Presents New Data Demonstrating Successful And Effective Transduction Of AAV5 Vector In The Presence Of Pre-Existing Neutralizing Antibodies In Non-Human Primates     5/10/2017
BioMarin (BMRN) Receives Access To Priority Medicines (PRIME) Regulatory Support From EMA For BMN 270 Gene Therapy In Hemophilia A     2/2/2017
Swedish Orphan Biovitrum Release: First Patients Enrolled In 24 Month Real-World Study Evaluating Effectiveness Of Elocta     1/19/2017
BioMarin (BMRN) Release: Bay Area Biotech Solidifies Status as Top Dog in Hemophilia A Gene Therapy     1/10/2017
CSL Behring Release: AFSTYLA, For Haemophilia A, Receives European Commission Approval     1/9/2017
HEMA Biologics Announced Today The Acceptance By FDA Of The Submitted Biologic License Application For Coagulation Factor Viia Recombinant, (Eptacog Beta Activated)     1/9/2017
Sangamo (SGMO) Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A     1/5/2017
Health Canada Approves CSL Behring's AFSTYLA For The Treatment Of Hemophilia A     12/15/2016
Sangamo (SGMO) Presents Hemophilia A Program Data At The 2016 American Society of Hematology Meeting     12/6/2016
Alnylam (ALNY) Reports Positive Interim Clinical Results For Fitusiran From Ongoing Phase 2 Open Label Extension Study In Patients With Hemophilia A Or B Without Inhibitors     12/5/2016